ResMed (RMD) director Form 4 shows 17,796 shares owned

ResMed Inc. (RMD) reported insider information for director Richard Sulpizio on a Form 4.

Rhea-AI Filing Summary

ResMed Inc. (RMD) reported insider information for director Richard Sulpizio on a Form 4. Following the reported activity, he beneficially owned 17,796 shares of ResMed common stock in direct ownership. The filing also notes that Sulpizio ceased to serve as a director at the conclusion of ResMed’s 2025 annual meeting of stockholders held on November 19, 2025, marking his departure from the company’s board.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SULPIZIO RICHARD

Role Director

Type	Security	Shares	Price	Value
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock — 17,796 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ResMed Inc. (RMD) report in this Form 4 filing?

ResMed Inc. reported insider information for director Richard Sulpizio, including his beneficial ownership of ResMed common stock and the end of his board service.

How many ResMed (RMD) shares does Richard Sulpizio beneficially own after the reported transaction?

After the reported transaction, Richard Sulpizio beneficially owned 17,796 shares of ResMed common stock in direct ownership.

What is Richard Sulpizio’s relationship to ResMed Inc. (RMD)?

Richard Sulpizio is identified in the filing as a director of ResMed Inc. and the Form 4 is filed by one reporting person.

Did Richard Sulpizio leave the ResMed (RMD) board?

Yes. The filing states that Richard Sulpizio ceased to serve as a director at the conclusion of the 2025 annual meeting of stockholders held on November 19, 2025.

What type of securities are reported in this ResMed (RMD) Form 4?

The Form 4 reports holdings of ResMed common stock as non-derivative securities beneficially owned by the reporting person.

Is this ResMed (RMD) Form 4 filed by multiple insiders?

No. The filing indicates that it is a Form filed by one reporting person, namely director Richard Sulpizio.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/21/2025 - 02:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SULPIZIO RICHARD

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock								17,796	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Reporting Person ceased to serve as a director at the conclusion of the 2025 annual meeting of stockholders held on November 19, 2025.

	Richard Sulpizio, director	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.